Suven Life Sciences on Saturday said that it had presented clinical Phase-I data for SUVN-502, a drug for Alzheimer's Disease, at the 2009 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD-2009) in Vienna, Austria.
In a press release here, Suven Life Sciences claimed SUVN-502 was intended for symptomatic treatment of Alzheimer's Disease and other disorders of memory and cognition like Attention Deficient hyperactivity, Parkinsons and Schizophrenia.The resaearch was conducted at Basel in Switzerland under a Clinical Trial Application (CTA) approved by SwissMedic, the regulatory authority of Switzerland for therapeutic products.
The study, the company claimed, demonstrated SUVN-502 was well tolerated by the subjects at all dose levels with no clinically significant changes of vital sign parameters or serious or significant adverse events.Company CEO Venkat Jasti said ''we are very much pleased with the results of Phase-1 single ascending and multiple ascending studies with SUVN-502 in Switzerland.The company targets launching SUVN-502 in later part of 2013 or early 2014. Other molecules in the same category, currently under development, include GSK's molecule presently in Phase II.